Arvinas Earnings Call: PROTAC Breakthrough and New Risks

Arvinas Holding Company ((ARVN)) has held its Q1 earnings call. Read on for the main highlights of the call.

Arvinas’ latest earnings call struck an upbeat tone despite some notable headwinds. Management framed the landmark FDA nod for VEPPANU and a major Rigel partnership as proof that its targeted protein degradation platform is now clinically and commercially validated. While revenue dropped sharply and cash usage remained significant, executives emphasized a strengthened balance sheet, tighter cost controls, and a multi-asset pipeline advancing in parallel.

First PROTAC Approval Puts VEPPANU and Platform in Spotlight

The FDA’s approval of VEPPANU for ESR1‑mutant ER+/HER2‑ advanced breast cancer marked the first-ever heterobifunctional PROTAC degrader to reach the market. Arvinas stressed that this milestone, achieved with partner Pfizer, goes beyond a single product win and materially de‑risks the entire modality, reinforcing investor confidence that PROTACs can become a durable new treatment class.

Rigel Deal Unlocks Commercial Path and Shared Economics

Arvinas and Pfizer granted Rigel a global license covering commercialization, development, and manufacturing of VEPPANU, with Arvinas and Pfizer splitting out-license economics 50/50. Management highlighted expected upfront, near-term, and approval-related milestones, plus royalties, as meaningful non-dilutive cash inflows, even though some international financial terms remain undisclosed.

Cash Runway Extends Into Late Decade Despite Burn

The company ended Q1 2026 with $614.9 million in cash, cash equivalents, and marketable securities, down from $685.4 million at year-end 2025. Even with the $70.5 million sequential decline, Arvinas reiterated that its current resources should fund operations and key data readouts for four Phase 1 programs into the second half of 2028, limiting near-term financing pressure.

Cost Cuts Reshape 2026 Expense Base

Arvinas reported substantial non-GAAP cost reductions, with R&D down $25.0 million (32%) and G&A down $10.1 million (44%) year over year, driving total non-GAAP expenses to $67.3 million. Executives framed the new 2026 cost structure as largely in place, improving financial flexibility, though they acknowledged that lower R&D and G&A may temper the pace of some activities.

ARV-102 Delivers Biomarker Wins in Parkinson’s Disease

In its LRRK2 program, Phase 1 data for ARV‑102 showed at least 50% reductions in CSF LRRK2 levels by day 14, sustained through day 28, alongside dose-dependent reductions in downstream biomarkers like CD68 and GPNMB. The drug was generally well tolerated with no serious adverse events over 28 days, supporting its potential as a differentiated Parkinson’s therapy targeting disease biology.

ARV-806 Boasts Potent KRAS G12D Degradation and Fast Enrollment

Preclinical data for ARV‑806 demonstrated roughly 25–40 times higher potency than clinical-stage KRAS G12D inhibitors and degraders, with more than 90% degradation lasting seven days after a single dose. Phase 1 dose-escalation enrollment completed ahead of schedule, and the company expects initial clinical data later this year, setting up an important proof-of-concept moment in a hotly contested oncology niche.

ARV-393 Shows Early Responses and Combination Ambitions

For ARV‑393, targeting BCL6, Arvinas reported early clinical responses in relapsed or refractory B- and T-cell lymphomas at exposures below predicted efficacious levels and noted strong BCL6 degradation. The company has also initiated a combination trial with glofitamab in diffuse large B-cell lymphoma, aiming to enhance efficacy and expand the asset’s potential role in hematologic cancers.

Broad Pipeline and Translational Record Underpin Platform Story

Management underscored the breadth of its pipeline, with four Phase 1 programs currently running and additional candidates preparing to enter the clinic. Discovery efforts include ARV‑6723, an HPK1 immuno-oncology degrader, and an oral pan‑KRAS program slated for first-in-human studies later this year, all supported by experience dosing more than 2,000 patients and volunteers across its portfolio.

Revenue Collapse Reflects Collaboration Accounting Shift

Q1 2026 revenue fell to $15.6 million from $188.8 million in the prior-year quarter, a roughly 92% decline tied mainly to lower recognized revenue from the vepdegestrant collaboration as estimated remaining program costs changed. Management framed the drop as an accounting-driven reset rather than a collapse in underlying demand, but acknowledged the optics of such a sharp top-line contraction.

Cash Balance Declines but Remains Comfortable

The quarter-over-quarter reduction in cash and equivalents to $614.9 million, a $70.5 million decrease, reflected ongoing operating burn and a lull in new upfront or collaboration receipts. Executives argued that upcoming milestones tied to VEPPANU and Rigel, combined with disciplined spending, should moderate future cash outflows and support the multiyear runway guidance.

ARV-102 Faces U.S. Clinical Hold While Europe Progresses

The FDA placed the planned U.S. Phase 1b study of ARV‑102 in PSP on clinical hold pending final chronic nonhuman primate toxicology data, now expected by mid‑2026. While this delays U.S. patient dosing, Arvinas noted that European trials remain unaffected and maintained its timeline for a global Phase 2 start, assuming the requested data satisfy regulators.

Lower R&D and G&A Highlight Trade-Offs of Cost Cutting

On a GAAP basis, R&D fell to $60.3 million from $90.8 million year over year, while G&A declined to $19.1 million from $26.6 million, underscoring management’s push for efficiency. The company acknowledged that while these cuts improve the P&L and extend runway, they also likely reflect re-prioritization and restructuring that could slow some early-stage or non-core initiatives.

KRAS and RAS Landscape Raises Execution Risks

Arvinas positioned ARV‑806 and its pan‑KRAS program as highly differentiated on potency, but conceded that the broader KRAS/RAS space is intensely competitive with recent transformative pan‑RAS data from rivals. Safety concerns seen with some pan‑RAS agents, including dermatologic and other toxicities, mean Arvinas must not only show strong efficacy but also a clean tolerability profile to win share.

VEPPANU’s Global Path Still Taking Shape

While Rigel now holds global rights to VEPPANU, it will need to sublicense or partner in various regions, and Arvinas did not disclose detailed international royalty or economics terms. That leaves investors with uncertainty about the timing, scale, and regional contribution of non‑U.S. revenue, even as the U.S. launch and approval milestone remain near-term value drivers.

Guidance Emphasizes Runway, Cost Discipline, and Milestones

Arvinas reiterated that its $614.9 million in cash, cash equivalents, and marketable securities should fund operations into the second half of 2028, even as revenue resets lower following the vepdegestrant collaboration changes. Management guided to largely completed cost reductions by mid‑2026 and flagged key upcoming catalysts, including ARV‑102 U.S. Phase 1b initiation by end‑2026, clinical updates for ARV‑806 and ARV‑393 later this year, ARV‑6723 entering the clinic, and anticipated VEPPANU-related milestone cash inflows.

Arvinas’ call painted a picture of a company transitioning from platform promise to commercial reality, with VEPPANU’s approval and the Rigel deal serving as validating milestones. Despite sharp revenue declines, cash burn, regulatory delays, and competitive pressures in KRAS, the extended runway, tightened cost base, and rich catalyst calendar suggest that the risk-reward profile remains skewed toward long-term upside for patient and equity holders alike.